106 related articles for article (PubMed ID: 15138713)
1. Synergistic effects of ICI 182,780 on the cytotoxicity of cisplatin in cervical carcinoma cell lines.
García-López P; Rodríguez-Dorantes M; Pérez-Cárdenas E; Cerbón M; Mohar-Betancourt A
Cancer Chemother Pharmacol; 2004 Jun; 53(6):533-40. PubMed ID: 15138713
[TBL] [Abstract][Full Text] [Related]
2. Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells.
De Vincenzo R; Scambia G; Benedetti Panici P; Fattorossi A; Bonanno G; Ferlini C; Isola G; Pernisco S; Mancuso S
Int J Cancer; 1996 Nov; 68(3):340-8. PubMed ID: 8903476
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin cytotoxicity is increased by mifepristone in cervical carcinoma: an in vitro and in vivo study.
Jurado R; Lopez-Flores A; Alvarez A; García-López P
Oncol Rep; 2009 Nov; 22(5):1237-45. PubMed ID: 19787245
[TBL] [Abstract][Full Text] [Related]
4. Synergistic anticancer activity of Thiazolo[5,4-b]quinoline derivative D3CLP in combination with cisplatin in human cervical cancer cells.
González-Sánchez I; Lira-Rocha A; Navarrete A; Loza-Mejía MA; Coronel-Cruz C; Mendoza-Rodríguez CA; Cerbón MA
Anticancer Res; 2012 Dec; 32(12):5159-65. PubMed ID: 23225412
[TBL] [Abstract][Full Text] [Related]
5. Antihormonal agents as a strategy to improve the effect of chemo-radiation in cervical cancer: in vitro and in vivo study.
Segovia-Mendoza M; Jurado R; Mir R; Medina LA; Prado-Garcia H; Garcia-Lopez P
BMC Cancer; 2015 Jan; 15():21. PubMed ID: 25622528
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor isoform-specific induction of progesterone receptors in human osteoblasts.
Rickard DJ; Waters KM; Ruesink TJ; Khosla S; Katzenellenbogen JA; Katzenellenbogen BS; Riggs BL; Spelsberg TC
J Bone Miner Res; 2002 Apr; 17(4):580-92. PubMed ID: 11918216
[TBL] [Abstract][Full Text] [Related]
7. The pure antiestrogen ICI 182,780 inhibits progestin-induced transcription.
Nawaz Z; Stancel GM; Hyder SM
Cancer Res; 1999 Jan; 59(2):372-6. PubMed ID: 9927049
[TBL] [Abstract][Full Text] [Related]
8. Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones.
Havrilesky LJ; McMahon CP; Lobenhofer EK; Whitaker R; Marks JR; Berchuck A
J Soc Gynecol Investig; 2001; 8(2):104-13. PubMed ID: 11336882
[TBL] [Abstract][Full Text] [Related]
9. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
Pink JJ; Jordan VC
Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307
[TBL] [Abstract][Full Text] [Related]
10. Anti-estrogenic activities of indole-3-carbinol in cervical cells: implication for prevention of cervical cancer.
Yuan F; Chen DZ; Liu K; Sepkovic DW; Bradlow HL; Auborn K
Anticancer Res; 1999; 19(3A):1673-80. PubMed ID: 10470100
[TBL] [Abstract][Full Text] [Related]
11. [Adenovirus-delivered tissue inhibitor of metalloproteinases-3 transfection increases the sensitivity of cervical cancer cells to cisplatin].
Zhang Y; Lin C; Qian HL; Lang JH; Fu M; Zhang XY; Liang X; Duan H; Xiang Y
Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):25-9. PubMed ID: 17575689
[TBL] [Abstract][Full Text] [Related]
12. Dehydroepiandrosterone inhibits the proliferation and induces the death of HPV-positive and HPV-negative cervical cancer cells through an androgen- and estrogen-receptor independent mechanism.
Girón RA; Montaño LF; Escobar ML; López-Marure R
FEBS J; 2009 Oct; 276(19):5598-609. PubMed ID: 19702826
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling in Ishikawa cells: a fingerprint for estrogen active compounds.
Boehme K; Simon S; Mueller SO
Toxicol Appl Pharmacol; 2009 Apr; 236(1):85-96. PubMed ID: 19371625
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of the antitumor efficacy of the antiprogestin, onapristone, by combination with the antiestrogen, ICI 164384.
Nishino Y; Schneider MR; Michna H
J Cancer Res Clin Oncol; 1994; 120(5):298-302. PubMed ID: 8126059
[TBL] [Abstract][Full Text] [Related]
15. Activity of cisplatin and ICI 182,780 on estrogen receptor negative ovarian cancer cells: cell cycle and cell replication rate perturbation, chromatin texture alteration and apoptosis induction.
Ercoli A; Battaglia A; Raspaglio G; Fattorossi A; Alimonti A; Petrucci F; Caroli S; Mancuso S; Scambia G
Int J Cancer; 2000 Jan; 85(1):98-103. PubMed ID: 10585591
[TBL] [Abstract][Full Text] [Related]
16. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
17. Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer.
Ma X; Zhang J; Liu S; Huang Y; Chen B; Wang D
Cancer Chemother Pharmacol; 2012 Feb; 69(2):485-94. PubMed ID: 21842204
[TBL] [Abstract][Full Text] [Related]
18. A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780.
Huynh H; Yang XF; Pollak M
Cell Growth Differ; 1996 Nov; 7(11):1501-6. PubMed ID: 8930399
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.
Robertson JF; Nicholson RI; Bundred NJ; Anderson E; Rayter Z; Dowsett M; Fox JN; Gee JM; Webster A; Wakeling AE; Morris C; Dixon M
Cancer Res; 2001 Sep; 61(18):6739-46. PubMed ID: 11559545
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis in cervical cancer cells: implications for adjunct anti-estrogen therapy for cervical cancer.
Chen D; Carter TH; Auborn KJ
Anticancer Res; 2004; 24(5A):2649-56. PubMed ID: 15517869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
